Sign Up Today and Learn More About Grey Wolf Therapeutics Stock
Invest in or calculate the value of your shares in Grey Wolf Therapeutics or other pre-IPO companies through EquityZen's platform.
Grey Wolf Therapeutics Stock (GRWT)
Small molecules to increase tumor detection by the immune system
About Grey Wolf Therapeutics Stock
Founded
2017
Industries
Apps, Software, Artificial Intelligence
Grey Wolf Therapeutics Press Mentions
Stay in the know about the latest news on Grey Wolf Therapeutics
Genomics and Greywolf partner in autoimmune diseases
bioworld • May 01, 2026
Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases
biospace • Apr 30, 2026
Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases
prnewswire • Apr 30, 2026
Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases
morningstar • Apr 30, 2026
Greywolf Therapeutics appoints Edwin Moses as Chair
biospace • Apr 16, 2026
Grey Wolf Therapeutics Management
Leadership team at Grey Wolf Therapeutics
Board Member
Marie-Claire Peakman
Board Member
Sally Dewhurst
Join now and verify your accreditation status to gain access to:
- Grey Wolf Therapeutics Current Valuation
- Grey Wolf Therapeutics Stock Price
- Grey Wolf Therapeutics Management
- Available deals in Grey Wolf Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Grey Wolf Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Grey Wolf Therapeutics Revenue and Financials
- Grey Wolf Therapeutics Highlights
- Grey Wolf Therapeutics Business Model
- Grey Wolf Therapeutics Risk Factors
- Grey Wolf Therapeutics Research Report from SACRA Research
Trading Grey Wolf Therapeutics Stock
How to invest in Grey Wolf Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Grey Wolf Therapeutics through EquityZen funds. These investments are made available by existing Grey Wolf Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Grey Wolf Therapeutics stock?
Shareholders can sell their Grey Wolf Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 450K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
